Aptinyx Inc (NASDAQ:APTX) Expected to Post Quarterly Sales of $950,000.00

Brokerages expect Aptinyx Inc (NASDAQ:APTX) to report $950,000.00 in sales for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for Aptinyx’s earnings. The lowest sales estimate is $890,000.00 and the highest is $1.00 million. Aptinyx reported sales of $940,000.00 in the same quarter last year, which suggests a positive year-over-year growth rate of 1.1%. The business is expected to announce its next earnings report on Tuesday, November 12th.

On average, analysts expect that Aptinyx will report full year sales of $3.78 million for the current fiscal year, with estimates ranging from $3.56 million to $4.00 million. For the next year, analysts expect that the firm will report sales of $2.89 million, with estimates ranging from $1.78 million to $4.00 million. Zacks Investment Research’s sales averages are an average based on a survey of research firms that follow Aptinyx.

Aptinyx (NASDAQ:APTX) last announced its earnings results on Monday, August 12th. The company reported ($0.36) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.16. The business had revenue of $0.93 million during the quarter, compared to analyst estimates of $0.95 million. Aptinyx had a negative net margin of 1,166.40% and a negative return on equity of 37.53%.

APTX has been the subject of several analyst reports. Cantor Fitzgerald restated a “buy” rating on shares of Aptinyx in a research note on Tuesday, April 30th. Zacks Investment Research upgraded Aptinyx from a “hold” rating to a “buy” rating and set a $4.25 price objective for the company in a research note on Tuesday, July 16th. JPMorgan Chase & Co. lowered Aptinyx from a “neutral” rating to an “underweight” rating in a research note on Tuesday. Cowen restated a “buy” rating on shares of Aptinyx in a research note on Monday, June 10th. Finally, Svb Leerink initiated coverage on Aptinyx in a research note on Thursday, June 20th. They issued an “outperform” rating and a $12.00 price objective for the company. One research analyst has rated the stock with a sell rating and seven have issued a buy rating to the company. Aptinyx presently has a consensus rating of “Buy” and an average price target of $12.71.

Large investors have recently bought and sold shares of the company. Great West Life Assurance Co. Can purchased a new stake in Aptinyx in the 4th quarter worth $40,000. Metropolitan Life Insurance Co. NY increased its stake in Aptinyx by 356.6% in the 4th quarter. Metropolitan Life Insurance Co. NY now owns 7,237 shares of the company’s stock worth $120,000 after buying an additional 5,652 shares in the last quarter. Barclays PLC increased its stake in Aptinyx by 87.1% in the 4th quarter. Barclays PLC now owns 9,323 shares of the company’s stock worth $154,000 after buying an additional 4,340 shares in the last quarter. Gabelli Funds LLC purchased a new stake in Aptinyx in the 1st quarter worth $44,000. Finally, Bank of America Corp DE increased its stake in Aptinyx by 430.0% in the 4th quarter. Bank of America Corp DE now owns 13,213 shares of the company’s stock worth $218,000 after buying an additional 10,720 shares in the last quarter. Hedge funds and other institutional investors own 58.30% of the company’s stock.

APTX traded up $0.03 during mid-day trading on Wednesday, reaching $3.25. 134,733 shares of the company traded hands, compared to its average volume of 342,933. The firm has a market cap of $118.47 million, a PE ratio of -1.23 and a beta of -0.03. The stock’s fifty day moving average is $3.62. Aptinyx has a 52-week low of $2.88 and a 52-week high of $32.25.

Aptinyx Company Profile

Aptinyx Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. It is developing NYX-2925 that is in Phase II clinical trial for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II exploratory clinical trial for fibromyalgia; and NYX-783, an NMDAr receptor that is in Phase I clinical trial for the treatment of post-traumatic stress disorder.

Read More: What is Compound Annual Growth Rate (CAGR)?

Get a free copy of the Zacks research report on Aptinyx (APTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aptinyx (NASDAQ:APTX)

Receive News & Ratings for Aptinyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptinyx and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit